Eurasian Journal of Pulmonology

LETTER TO EDITOR
Year
: 2020  |  Volume : 22  |  Issue : 1  |  Page : 71-

Proadrenomedullin determining clinical severity and analyzing prognostic value for pneumonia


Sedat Demirsoy1, Oguzhan Okutan1, Zafer Kartaloglu1, Dilaver Tas2, Omer Ayten1, Kadir Canoglu1,  
1 Department of Pulmonology, Sultan Abdulhamid Han Research Hospital, Istanbul, Turkey
2 Department of Pulmonology Baskent University, Istanbul Education and Research Hospital, Istanbul, Turkey

Correspondence Address:
Dr. Dilaver Tas
Department of Pulmonology, Baskent University, Istanbul Education and Research Hospital, Istanbul
Turkey




How to cite this article:
Demirsoy S, Okutan O, Kartaloglu Z, Tas D, Ayten O, Canoglu K. Proadrenomedullin determining clinical severity and analyzing prognostic value for pneumonia.Eurasian J Pulmonol 2020;22:71-71


How to cite this URL:
Demirsoy S, Okutan O, Kartaloglu Z, Tas D, Ayten O, Canoglu K. Proadrenomedullin determining clinical severity and analyzing prognostic value for pneumonia. Eurasian J Pulmonol [serial online] 2020 [cited 2020 Dec 6 ];22:71-71
Available from: https://www.eurasianjpulmonol.com/text.asp?2020/22/1/71/283637


Full Text



Sir,

Thanks for your interest. As you stated, proadrenomedullin (proADM) is an interesting biomarker, and many researchers studied its value for various physiologic and also pathologic conditions. Many noninfectious situations alter proADM levels, but Kutz et al. encourage that “reinforce the concept of using biomarkers in algorithms with widely separated cutoffs despite statistically significant associations of some preanalytic factors and biomarker levels.”[1] Our primary aim was to determine and compare proADM with clinical severity scores for pneumonia and validate its value with regard to that of previous studies, at a prospective work. We found no statistical superiority in favor of proADM. In a meta-analysis, Liu et al. concluded that proADM sensitivity and specificity – to predict mortality in community-acquired pneumonia – were 0.74 (95% confidence interval [CI]: 0.67–0.79) and 0.73 (95% CI: 0.70–0.77), respectively.[2] As a result, there is no sufficient evidence yet to rely on only proADM for pneumonia severity instead of clinical scores as its value was altered by multiple conditions. Eventually combining with other biomarkers and scores is much more promising.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Kutz A, Grolimund E, Christ-Crain M, Thomann R, Falconnier C, Hoess C, et al. Pre-analytic factors and initial biomarker levels in community-acquired pneumonia patients. BMC Anesthesiol 2014;14:102.
2Liu D, Xie L, Zhao H, Liu X, Cao J. Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: A systematic review and meta-analysis. BMC Infect Dis 2016;16:232.